Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
Open Access
- 9 December 2019
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 31 (3), 412-421
- https://doi.org/10.1016/j.annonc.2019.11.018
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
- Genentech
- F. Hoffmann-La Roche
- Genentech
- Incyte
- Genentech
- Merck Serono
- Pfizer
- Sequenom
- Foundation Medicine
- Guardant Health
- Grifols
- Konica Minolta
- Debiopharm
- Boehringer Ingelheim
- OmniSeq
- ImmunoGen
- VentiRx
- Plexxikon
- Merck
- AstraZeneca
- Advaxis
- Bristol-Myers Squibb
- AbbVie
- Aileron
- AstraZeneca
- Bayer
- Calithera
- Curis
- CytomX
- eFFECTOR
- Guardant Health
- Daiichi-Sankyo
- Debiopharm Group
- Genentech
- GlaxoSmithKline
- Novartis
- Pfizer
- PUMA
- Taiho
- Zymeworks
- Astellas Pharma
- AstraZeneca
- Genentech
- Novartis
- AbbVie
- Acerta Pharma
- Aeglea BioTherapeutics
- Amgen
- ARMO BioSciences
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Celldex
- Clovis Oncology
- Daiichi-Sankyo
- EMD Serono
- Foundation Medicine
- GlaxoSmithKline
- G1 Therapeutics
- Roche
- Genentech
- GRAIL
- Ipsen
- Lilly
- Merck
- Millennium
- Nektar
- Novartis
- Neon Therapeutics
- Pfizer
- Takeda
- Tesaro
- Transgene
- University of Texas Southwestern Medical Center
- Simmons Cancer Center
- Puma Biotechnology
- Agios
- ARCH
- Arvinas
- AstraZeneca
- BioAtla
- Biomed Valley Discoveries
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- CicloMed
- CytomX Therapeutics
- eFFECTOR Therapeutics
- Gilead Sciences
- GlaxoSmithKline
- Harpoon Therapeutics
- Immunocore
- Incyte
- Janssen
- Jiangsu Hengrui Medicine
- Jounce Therapeutics
- Kyocera
- Lilly
- Loxo
- MacroGenics
- MedImmune
- Merck
- Millennium
- Moderna Therapeutics
- Novartis
- Revolution Medicines
- Roche
- Genentech
- Seattle Genetics
- Takeda
- Tessaro
- TG Therapeutics
- Verastem
- Vertex
- Astellas Pharma
- Exelixis
- Janssen Biotech
- Bristol-Myers Squibb
This publication has 24 references indexed in Scilit:
- Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic AlterationsClinical Cancer Research, 2016
- Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast CancerClinical Cancer Research, 2016
- Risk Factors and Survival Associated with Distant Metastasis in Patients with Carcinoma of the Salivary GlandAnnals of Surgical Oncology, 2016
- What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)Annals Of Oncology, 2016
- Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutationsHead & Neck, 2015
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsThe New England Journal of Medicine, 2015
- Genomic landscape of salivary gland tumorsOncotarget, 2015
- K5/K14-positive cells contribute to salivary gland-like breast tumors with myoepithelial differentiationLaboratory Investigation, 2013
- Human epidermal receptor 2–amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti–vascular endothelial growth factor combination treatmentHead & Neck, 2013
- HER2 Expression in Salivary Gland CarcinomasClinical Cancer Research, 2004